 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- vepsitamab (AMG 199) / Amgen
Enrollment change, Trial termination: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov) - Jun 22, 2023
P1, N=58, Terminated, Sponsor: Amgen
N=240 --> 58 | Active, not recruiting --> Terminated; Business decision
- || vepsitamab (AMG 199) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov) - Feb 8, 2023
P1, N=240, Active, not recruiting, Sponsor: Amgen
N=240 --> 58 | Active, not recruiting --> Terminated; Business decision Recruiting --> Active, not recruiting | Trial completion date: Feb 2027 --> May 2023 | Trial primary completion date: Aug 2025 --> May 2023
- || vepsitamab (AMG 199) / Amgen
Trial completion date, Trial primary completion date: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov) - Nov 18, 2022
P1, N=240, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | Trial completion date: Feb 2027 --> May 2023 | Trial primary completion date: Aug 2025 --> May 2023 Trial completion date: Oct 2025 --> Dec 2026 | Trial primary completion date: Mar 2024 --> Jun 2025
- || vepsitamab (AMG 199) / Amgen
Enrollment change, Trial completion date, Trial primary completion date: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov) - Nov 10, 2022
P1, N=240, Recruiting, Sponsor: Amgen
Trial completion date: Oct 2025 --> Dec 2026 | Trial primary completion date: Mar 2024 --> Jun 2025 N=165 --> 240 | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Jun 2025 --> Mar 2024
- || vepsitamab (AMG 199) / Amgen
Trial completion date, Trial primary completion date: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov) - Nov 3, 2022
P1, N=165, Recruiting, Sponsor: Amgen
N=165 --> 240 | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Jun 2025 --> Mar 2024 Trial completion date: Apr 2025 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Jun 2025
- || vepsitamab (AMG 199) / Amgen
Trial primary completion date: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov) - Dec 10, 2021
P1, N=165, Recruiting, Sponsor: Amgen
Trial completion date: Apr 2025 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Jun 2025 Trial primary completion date: Apr 2025 --> Aug 2023
- || vepsitamab (AMG 199) / Amgen
Trial completion date, Trial primary completion date: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov) - Oct 21, 2021
P1, N=150, Recruiting, Sponsor: Amgen
Trial primary completion date: Apr 2025 --> Aug 2023 Trial completion date: Nov 2025 --> Apr 2025 | Trial primary completion date: Nov 2025 --> Apr 2025
- |||| AMG 199 / Amgen
interesting... this trial expanded to #Colorectal Cancer in 2020 Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, & Pancreatic Cancers ASCO20 description of AMG 199 Dr @pashtoonkasi https://t.co/YOzx2iuZIn https://t.co/Qn17Pj9Tsy (Twitter) - Sep 14, 2021
- || vepsitamab (AMG 199) / Amgen
Enrollment change, Trial completion date, Trial primary completion date: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov) - Sep 14, 2021
P1, N=150, Recruiting, Sponsor: Amgen
Trial completion date: Nov 2025 --> Apr 2025 | Trial primary completion date: Nov 2025 --> Apr 2025 N=70 --> 150 | Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Jun 2025 --> Nov 2025
- || vepsitamab (AMG 199) / Amgen
Trial completion date, Trial primary completion date: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov) - Nov 30, 2020
P1, N=70, Recruiting, Sponsor: Amgen
N=70 --> 150 | Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Jun 2025 --> Nov 2025 Trial completion date: Mar 2024 --> Jun 2025 | Trial primary completion date: Sep 2022 --> Jun 2025
- || vepsitamab (AMG 199) / Amgen
Trial completion date, Trial primary completion date: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov) - May 17, 2020
P1, N=70, Recruiting, Sponsor: Amgen
Trial completion date: Mar 2024 --> Jun 2025 | Trial primary completion date: Sep 2022 --> Jun 2025 Trial completion date: Sep 2026 --> Mar 2024 | Trial primary completion date: Mar 2024 --> Sep 2022
- AMG 199 / Amgen, AMG 910 / Amgen
Preclinical evaluation of BiTE®immune therapy targeting MUC17 or CLDN18.2 for gastric cancer (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_3577;
In contrast, treatment with AMG 910 led to direct cell killing of CLDN18.2-expressing gastric mucosal cells in NHP, a finding which was fully reversible once treatment was stopped. AMG 199 and AMG 910 may offer the potential to improve outcomes in advanced gastric patients worldwide.
- irinotecan / Generic mfg.
[VIRTUAL] A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_224;
P1
Legal entity responsible for the study Amgen, Inc. Funding Amgen, Inc.
- irinotecan / Generic mfg.
[VIRTUAL] Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer. (Poster Board 257) - Feb 27, 2020 - Abstract #ASCO2020ASCO_535;
P1
For more information, please contact Amgen Medical Information: medinfo@amgen.com. Research Funding: Amgen
- ||| vepsitamab (AMG 199) / Amgen
Enrollment open, Trial completion date, Trial primary completion date: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov) - Jan 15, 2020
P1, N=70, Recruiting, Sponsor: Amgen
Research Funding: Amgen Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Sep 2026 | Trial primary completion date: Jul 2022 --> Feb 2024
- | vepsitamab (AMG 199) / Amgen
Trial completion date, Trial initiation date, Trial primary completion date: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov) - Nov 3, 2019
P1, N=70, Not yet recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Sep 2026 | Trial primary completion date: Jul 2022 --> Feb 2024 Trial completion date: Sep 2023 --> Dec 2023 | Initiation date: Dec 2020 --> Dec 2019 | Trial primary completion date: Mar 2022 --> Jul 2022
- | vepsitamab (AMG 199) / Amgen
New P1 trial: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov) - Oct 6, 2019
P1, N=70, Not yet recruiting, Sponsor: Amgen